SEC Form 4 · accession 0001209191-16-142556
Adamas Pharmaceuticals Inc · ADMS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael Bigham
Director
Period of report
Sep 20, 2016
Accepted (ET)
Sep 22, 2016 · 8:00 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001328143
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $18.09 | Sep 20, 2016 | A | 30,000 | A | — | Sep 19, 2026 | Common Stock | 30,000 | 30,000 | D |
Explanation of responses
- F11/3rd of the shares subject to the option shall vest and become exercisable on each of 9/20/2017, 9/20/2018 and 9/20/2019, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) as of each such date.